Nardos Temesgen, MD
Interventional Cardiology · Washington, DCNPI 1508250424
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,224 of the $7,501 with a category attached, or 69.6%. 27 manufacturers reported payments, led by Medtronic at 57.8% of the total. Reporting peaked in 2022 at $3,224 and has fallen 76.6% since, to $754 in 2025.
Across 158 payments — averaging $47.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$395
- Novartis$321
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$291
- Cardiovascular Systems Inc.$282
- Terumo Medical Corporation$241
- plus $2K from 21 others
What the payments were for
- Travel & lodging$2,20029%
- Food & beverage$5,22470%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 56 | $4,335 |
| Abbott | 5 | $395 |
| Novartis | 17 | $321 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $291 |
| Cardiovascular Systems Inc. | 4 | $282 |
| Terumo Medical Corporation | 2 | $241 |
| Chiesi USA, Inc. | 5 | $196 |
| Boston Scientific | 2 | $178 |
| Abiomed | 1 | $150 |
| Novo Nordisk | 6 | $144 |
| Actelion Pharmaceuticals US, Inc. | 4 | $110 |
| Atricure, Inc. | 4 | $95 |
| Johnson & Johnson | 4 | $79 |
| Merck | 4 | $79 |
| AstraZeneca | 4 | $74 |
| Amgen | 3 | $72 |
| Philips North America LLC | 3 | $59 |
| Edwards Lifesciences | 2 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Shockwave Medical, Inc | 2 | $51 |
| Scpharmaceuticals Inc. | 1 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| Boehringer Ingelheim | 2 | $43 |
| Pfizer | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$1,546
- ONYX FRONTIER$1,098
- Diamondback Coronary$242
- METACROSS OTW$182
- OPTICROSS$150
- COROFLOW$135
- KENGREAL$132
- COREVALVE EVOLUT R$125
- SYMPLICITY G3$124
- OPTIS$117
How this compares
Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $48,071 |
| EliquisApixaban | 40 | $37,789 |
| BrilintaTicagrelor | 13 | $14,782 |
| EntrestoSacubitril/Valsartan | 14 | $14,551 |
| Metoprolol Succinate | 97 | $1,146 |
| Rosuvastatin Calcium | 50 | $896 |
| Atorvastatin Calcium | 75 | $824 |
| Ezetimibe | 17 | $701 |
| ClopidogrelClopidogrel Bisulfate | 32 | $410 |
| Pantoprazole Sodium | 14 | $329 |
| Lisinopril | 17 | $319 |
| Losartan Potassium | 34 | $267 |
| Amlodipine Besylate | 21 | $226 |
| Carvedilol | 30 | $222 |
| Spironolactone | 25 | $186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $43 | $48,07141 claims |
| PfizerEliquis | $41 | $37,78940 claims |
| AstraZenecaBrilinta | $74 | $14,78213 claims |
| NovartisEntresto | $321 | $14,55114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Washington
- Ron WaksmanWashington$915K
- Toby RogersWashington$880K
- Augusto PichardWashington$180K
- Lowell SatlerWashington$112K
- Jonathan ReinerWashington$77K
- Brian CaseWashington$63K
- Horst SievertWashington$58K
- Nelson BernardoWashington$55K
- Ramesh MazhariWashington$41K
- Itshac Ben-DorWashington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.